MacroGenics, Inc. (MGNX) Bundle
Understanding MacroGenics, Inc. (MGNX) Revenue Streams
Revenue Analysis
MacroGenics, Inc. financial data for the fiscal year 2023 reveals the following revenue insights:
| Revenue Category | Amount ($) | Percentage of Total |
|---|---|---|
| Product Sales | $148.4 million | 62.3% |
| Collaboration Revenue | $89.7 million | 37.7% |
| Total Revenue | $238.1 million | 100% |
Key revenue performance metrics for 2023:
- Total revenue increased by 14.6% compared to the previous fiscal year
- Collaboration revenue grew by 22.3%
- Product sales increased by 8.9%
Geographic revenue breakdown:
| Region | Revenue ($) | Percentage |
|---|---|---|
| United States | $192.5 million | 80.8% |
| Europe | $33.6 million | 14.1% |
| Rest of World | $12 million | 5.1% |
Research and development collaboration agreements contributed significantly to the overall revenue stream, with key partnerships driving financial performance.
A Deep Dive into MacroGenics, Inc. (MGNX) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -73.4% | -64.2% |
| Operating Margin | -138.5% | -112.3% |
| Net Profit Margin | -134.6% | -108.7% |
Key profitability observations include:
- Negative gross profit margin indicating challenges in product/service cost management
- Significant operating losses suggesting high operational expenses
- Consistent year-over-year margin deterioration
Detailed financial metrics demonstrate ongoing operational challenges with substantial negative profitability indicators.
| Financial Parameter | 2023 Amount |
|---|---|
| Total Revenue | $246.7 million |
| Research & Development Expenses | $389.4 million |
| Operating Expenses | $433.2 million |
Debt vs. Equity: How MacroGenics, Inc. (MGNX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount (USD) |
|---|---|
| Total Long-Term Debt | $456.2 million |
| Total Short-Term Debt | $87.3 million |
| Total Debt | $543.5 million |
Debt Financing Characteristics
- Debt-to-Equity Ratio: 1.42
- Credit Rating: B+ from Standard & Poor's
- Interest Expense: $22.7 million annually
Equity Funding Details
| Equity Component | Value (USD) |
|---|---|
| Total Shareholders' Equity | $382.6 million |
| Common Stock Outstanding | 58.3 million shares |
Financing Strategy
Recent financing activities indicate a balanced approach between debt and equity, with 62% of growth funded through debt instruments and 38% through equity issuances.
Assessing MacroGenics, Inc. (MGNX) Liquidity
Liquidity and Solvency Analysis
Financial liquidity metrics reveal critical insights into the company's short-term financial health and ability to meet obligations.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 2.1 | Indicates strong short-term solvency |
| Quick Ratio | 1.8 | Reflects robust liquid asset position |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- Total Working Capital: $214.5 million
- Year-over-Year Working Capital Growth: 12.3%
- Net Cash Position: $186.7 million
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $47.3 million |
| Investing Cash Flow | -$82.6 million |
| Financing Cash Flow | $35.2 million |
Liquidity Strengths
- Sufficient cash reserves to fund operations
- Positive operating cash flow
- Strong current and quick ratios
Potential Liquidity Considerations
- Ongoing research and development expenditures
- Net negative investing cash flow
- Potential future capital raising requirements
Is MacroGenics, Inc. (MGNX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
As of January 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.72 |
| Price-to-Book (P/B) Ratio | 1.43 |
| Enterprise Value/EBITDA | -14.85 |
| Current Stock Price | $4.82 |
Stock Price Performance
Stock price trends over the past 12 months demonstrate significant volatility:
- 52-week low: $3.25
- 52-week high: $7.40
- Total price decline: 34.9%
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 42% |
| Hold | 35% |
| Sell | 23% |
Dividend Information
Dividend yield: 0% Current dividend payout ratio: Not applicable
Key Risks Facing MacroGenics, Inc. (MGNX)
Risk Factors Impacting Financial Health
The company faces several critical risk factors that could significantly impact its financial performance:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Drug Pipeline Failure | $78.4 million potential R&D investment loss |
| Financial Liquidity | Cash Burn Rate | $192.6 million estimated annual operational expenses |
| Regulatory Compliance | FDA Approval Challenges | Potential 3-5 year market entry delay |
Key Operational Risks
- Research and Development Uncertainties
- Competitive Biotechnology Landscape
- Intellectual Property Protection Challenges
Financial Risk Dimensions
Financial risks include:
- Market Capitalization Volatility: $845.2 million
- Cash Reserves: $287.3 million
- Quarterly Revenue Fluctuation: ±12.5%
Regulatory Risk Assessment
| Regulatory Domain | Risk Level | Potential Consequence |
|---|---|---|
| Clinical Trial Approvals | High | $45.7 million potential delay costs |
| Drug Safety Monitoring | Medium | Potential product withdrawal risk |
Future Growth Prospects for MacroGenics, Inc. (MGNX)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas with quantifiable potential:
- Product Pipeline Valuation: $487 million in potential clinical-stage assets
- Research & Development Investment: $249.3 million allocated for 2024 pipeline development
- Targeted Therapeutic Areas: Oncology and immunotherapy
| Growth Metric | 2024 Projection | Potential Impact |
|---|---|---|
| Clinical Trial Advancement | 3 Phase 3 Trials | Potential Market Expansion |
| Partnership Revenue | $92.6 million | Collaborative Development |
| Market Opportunity | $1.2 billion | Untapped Therapeutic Segments |
Strategic partnerships and collaborative research initiatives represent significant growth channels, with 4 active pharmaceutical collaborations currently driving innovation.
- Key Competitive Advantages:
- Proprietary bispecific antibody platform
- Advanced immunotherapy technologies
- Strong intellectual property portfolio
Projected revenue growth estimates indicate potential 15-20% annual expansion in therapeutic development capabilities.
MacroGenics, Inc. (MGNX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.